Previous Close | 0.0300 |
Open | 0.0300 |
Bid | 0.0000 |
Ask | 2.5200 |
Strike | 745.00 |
Expire Date | 2024-10-11 |
Day's Range | 0.0300 - 0.0300 |
Contract Range | N/A |
Volume | |
Open Interest | 7 |
U.S. Senator Elizabeth Warren has asked antitrust regulators to closely scrutinize a $16.5 billion deal in which Novo Nordisk's controlling shareholder would acquire contract drug manufacturer Catalent, saying it may give the pharmaceutical company an unlawful advantage in weight loss and obesity drugs. Novo Holdings, the investment firm that has a controlling interest in Novo Nordisk, signed a $16.5 billion deal to buy Catalent in February to boost supply of Wegovy, Novo's blockbuster GLP-1 weight loss drug.
NVS vs. LLY: Which Stock Is the Better Value Option?
S&P 500 earnings season is kicking off. And some companies are expected to put up some huge numbers — even bigger than Nvidia